BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	1.5M 1.72M 1.39M 1.29M 2.44M 162M 2.48M 16.63M 6.45M 80.04M 6.45M 6.3M 279M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 32.95M 26.62M 24.83M 46.79M 3.12B 47.62M 319M 124M 1.54B 124M 121M 5.36B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

25-10-27	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-02	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-09-28	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-28	BioSenic S.A. Announces Executive Changes	CI
24-09-30	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-09-29	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-09-17	BioSenic Deputy CEO Steps Down	MT
24-09-17	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
24-08-14	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
24-08-14	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
24-08-13	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
24-07-18	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
24-07-05	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25-09-25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
25-08-29	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
25-08-04	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
25-07-01	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	2021-12-31
Eric Halioua CHM	Chairman	-	2025-08-31
Virginie Miath BRD	Director/Board Member	-	2026-01-28

BioSenic SA Stock OTC Markets

Stocks

BNZPF

BE0974280126

Pharmaceuticals

Valuation: BioSenic SA

Latest news : BioSenic SA

Analysts' recommendations: BioSenic SA

Press Releases: BioSenic SA

News in other languages: BioSenic SA

Managers and Directors: BioSenic SA

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSENIC SA	-.--%	-.--%	-	-	1.49M
ELI LILLY AND COMPANY	-2.48%	+8.34%	+53.87%	+155.75%	1,097B
JOHNSON & JOHNSON	-1.76%	+6.23%	+66.27%	+53.44%	622B
ABBVIE INC.	-1.05%	+7.19%	+35.57%	+86.77%	449B
ROCHE HOLDING AG	+0.83%	+4.18%	+31.11%	+23.88%	334B
ASTRAZENECA PLC	-1.38%	+3.75%	+39.33%	+25.04%	294B
NOVARTIS AG	+0.30%	+2.56%	+31.62%	+40.64%	286B
NOVO NORDISK A/S	-0.10%	+2.23%	-28.43%	-42.77%	213B
AMGEN INC.	+0.44%	+4.35%	+29.69%	+63.10%	195B
GILEAD SCIENCES, INC.	+0.01%	+1.03%	+13.95%	+63.93%	157B
Average	-0.49%	+5.61%	+30.33%	+52.20%	405.19B
Weighted average by Cap.	-1.12%	+7.04%	+40.91%	+77.66%

	2023	2024
Net sales	336K 384K 310K 289K 545K 36.3M 555K 3.72M 1.44M 17.91M 1.44M 1.41M 62.4M	102K 117K 94.16K 87.83K 165K 11.02M 168K 1.13M 438K 5.44M 438K 428K 18.94M
Net income	-28.78M -32.88M -26.57M -24.78M -46.69M -3.11B -47.52M -319M -124M -1.53B -124M -121M -5.34B	-4.77M -5.45M -4.4M -4.11M -7.74M -515M -7.87M -52.8M -20.5M -254M -20.47M -20.01M -885M
Net Debt	28.04M 32.04M 25.88M 24.15M 45.49M 3.03B 46.31M 310M 121M 1.49B 120M 118M 5.21B	27.34M 31.23M 25.23M 23.54M 44.35M 2.95B 45.14M 303M 118M 1.46B 117M 115M 5.08B